2hon MSN
Targeting tumor supporting cells: Lipid nanoparticles advance CAR T success in pancreatic cancer
Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...
Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...
Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...
SMART control of CAR T cells is advancing cancer immunotherapy by improving precision, safety, and adaptability. Why Smart ...
A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...
While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...
CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...
A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results